Hisco announced that its subsidiary Shanghai Hisense Pharmaceutical Technology Co., Ltd. recently received the “Drug Clinical Trial Approval Notice” issued by the State Drug Administration and agreed to carry out clinical trials of HSK45019 tablets, HSK50042 tablets, HSK55718 for injections, and HSK36357 capsules.

Hisco announced that its subsidiary Shanghai Hisense Pharmaceutical Technology Co., Ltd. recently received the “Drug Clinical Trial Approval Notice” issued by the State Drug Administration and agreed to carry out clinical trials of HSK45019 tablets, HSK50042 tablets, HSK55718 for injections, and HSK36357 capsules.